# Population Based Germline Testing for Early Detection and Prevention of Cancer

> **NCT07498829** · NA · RECRUITING · sponsor: **Queen Mary University of London** · enrollment: 6000 (estimated)

## Conditions studied

- Breast Cancer Risk
- Ovarian Cancer Risk
- Cancer Gene Mutation

## Interventions

- **GENETIC:** Genetic testing for Cancer Susceptibility Genes (CSGs) (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2, MSH6) and personalised breast and ovarian cancer risk

## Key facts

- **NCT ID:** NCT07498829
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-18
- **Primary completion:** 2029-12
- **Final completion:** 2040-12
- **Target enrollment:** 6000 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07498829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07498829, "Population Based Germline Testing for Early Detection and Prevention of Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07498829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*